Unmet Needs and Future Perspectives in Transplant-Eligible NDMM

Video

A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      4 experts are featured in this series.
      Role of Bridging Therapy for CAR-T Patients
      4 experts are featured in this series.
      Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
      4 experts are featured in this series.
      Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
      4 experts are featured in this series.
      Overview of Process of CAR-T Therapy
      Related Content
      At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

      Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

      Roman Fabbricatore
      May 30th 2025
      Article

      At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy

      Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy

      Tim Cortese
      May 29th 2025
      Article

      A Chinese phase 2 trial found that anti-GPRC5D CAR T-cell therapy elicited an ORR of 84% in patients with relapsed or refractory multiple myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

      ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

      Tim Cortese
      May 20th 2025
      Article

      Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.

      In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

      Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

      Russ Conroy
      May 19th 2025
      Article

      Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.